Method for treating pervasive development disorders

• US 8,815,233 B2
• Filed: 04/16/2012
• Issued: 08/26/2014
• Est. Priority Date: 12/17/1999
• Status: Expired due to Term

• Current Assignee: Curemark LLC
• Original Assignee: Curemark LLC
• Inventors: Fallon, Joan M.
• Primary Examiner(s): BALLARD, KIMBERLY
• Application Number:
  US13/448,061
• Publication Number:
  US 20120207740A1
• Time in Patent Office: 862 Days
• Field of Search: None
• US Class Current: 424/94.21
• CPC Class Codes: A61B 5/1118 Determining activity level
• CPC Class Codes: A61B 5/16 Devices for psychotechnics using teaching or educational appliances G09B1/00 - G09B7/00; Testing reaction times ; Devices for evaluating the psychological state
• CPC Class Codes: A61B 5/165 Evaluating the state of mind, e.g. depression, anxiety
• CPC Class Codes: A61B 5/4848 Monitoring or testing the effects of treatment, e.g. of medication
• CPC Class Codes: A61K 38/2235 Secretins
• CPC Class Codes: A61K 38/465 acting on ester bonds (3.1), e.g. lipases, ribonucleases
• CPC Class Codes: A61K 38/47 acting on glycosyl compounds (3.2), e.g. cellulases, lactases
• CPC Class Codes: A61K 38/48 acting on peptide bonds (3.4)
• CPC Class Codes: A61K 38/4826 Trypsin (3.4.21.4) Chymotrypsin (3.4.21.1)
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/20 Pills, tablets, discs, rods A61K9/0004, A61K9/0007, A61K9/0056, A61K9/0065 take precedence; for reconstitution of a drink A61K9/0095
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: C12Q 1/37 involving peptidase or proteinase
• CPC Class Codes: C12Y 302/0102 Alpha-glucosidase (3.2.1.20)
• CPC Class Codes: C12Y 304/21001 Chymotrypsin (3.4.21.1)
• CPC Class Codes: C12Y 304/21004 Trypsin (3.4.21.4)
• CPC Class Codes: G01N 2333/976 Trypsin; Chymotrypsin
• CPC Class Codes: Y10S 435/803 Physical recovery methods, e.g. chromatography, grinding
• CPC Class Codes: Y10T 436/24 Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

A method of utilizing the chymotrypsin level of an individual as a measure of the success of secretin, other neuropeptides, and peptides or digestive enzyme administration to such individuals, and in particular, as a prognosticative of potential secretin, other neuropeptides, peptides, and digestive enzyme administration for persons having ADD, ADHD, Autism and other PDD related disorders.

Claims

1. A method of treating a pervasive development disorder (PDD), comprising:

administering a pharmaceutical composition comprising digestive enzymes to an individual having a PDD and a subnormal level of fecal chymotrypsin, wherein the digestive enzymes comprise amylase, protease and lipase, and wherein one or more symptoms of the PDD are ameliorated.

2. The method of claim 1, wherein the PDD is selected from the group consisting of Autism, Asperger'"'"'s, attention deficit disorder (ADD), and attention deficit hyperactive disorder (ADHD).

3. The method of claim 1, wherein the individual is from 2 to 4 years of age.

4. The method of claim 1, wherein the individual is from 1 to 6 years of age.

5. The method of claim 1, wherein the individual is from 5 to 12 years of age.

6. The method of claim 1, wherein the individual is from 7 to 12 years of age.

7. The method of claim 1, wherein the individual is from 2 to 12 years of age.

8. The method of claim 1, wherein the individual is from 1 to 12 years of age.

9. The method of claim 1, wherein the pharmaceutical composition is administered from 3-6 times per day.

10. The method of claim 1, wherein the pharmaceutical composition is administered 3 times per day.

11. The method of claim 1, wherein a dose of the digestive enzymes comprises from 4,000-20,000 U.S.P. units of lipases.

12. The method of claim 1, wherein a dose of the digestive enzymes comprises from 10,000-50,000 U.S.P. units of proteases.

13. The method of claim 1, wherein a dose of the digestive enzymes comprises from 10,000-60,000 U.S.P. units of amylases.

14. The method of claim 1, wherein a dose of the digestive enzymes comprises from 2,000-6,000 U.S.P. units of pancreatin.

15. The method of claim 1, wherein the digestive enzymes are provided as pancreatin.

16. The method of claim 1, wherein the individual'"'"'s fecal chymotrypsin level is determined by using an enzymatic spectrophotometry method.

17. The method of claim 16, wherein the enzymatic spectrophotometry method is performed at 30°

C.

18. The method of claim 1, wherein the individual'"'"'s determined fecal chymotrypsin level is below 8.4 U/gm.

19. The method of claim 1, wherein the individual'"'"'s determined fecal chymotrypsin level is below 8.4 U/gm but above or equal to 4.2 U/gm.

20. The method of claim 1, wherein the individual'"'"'s determined fecal chymotrypsin level is below 4.2 U/gm.